Company Overview

CBD of Denver Inc. (OTC Pink: CBDD) is a cannabis and cannabidiol-focused company that has historically operated through distribution, trading, and product commercialization activities tied to the European hemp and cannabis markets. The company has emphasized the sale of CBD products, cannabis flower distribution, and related wholesale activities, with a particular focus on the Swiss cannabis market, where low-THC cannabis products are legally permitted under specific regulatory frameworks. Public disclosures indicate that the company has pursued opportunities in both consumer-facing CBD products and business-to-business cannabis distribution channels.

The company evolved from earlier corporate activities into a cannabis-focused enterprise through acquisitions and restructuring initiatives designed to establish a presence in Europe’s regulated hemp and cannabis sectors. Its strategy has centered on leveraging Switzerland’s comparatively mature regulatory environment for CBD and low-THC cannabis products while pursuing broader European market exposure. Public filings and company disclosures indicate that revenue generation has primarily depended on wholesale cannabis transactions, product distribution, and affiliated cannabis operations. Some operational and financial details have varied across reporting periods, and certain historical business activities are difficult to independently verify in full based on available public sources.

Business Operations

CBD of Denver has historically reported operations tied to cannabis distribution, wholesale flower sales, and CBD-related commercial activities through subsidiaries and affiliated entities. The company’s operating structure has included exposure to European cannabis cultivation supply chains, wholesale trading relationships, and retail-oriented CBD channels. Public disclosures reference activities involving cannabis flower imports, distribution agreements, and participation in regulated hemp markets, particularly in Switzerland. Revenue has primarily been associated with product sales and wholesale cannabis transactions rather than proprietary pharmaceutical or biotechnology development.

The company’s operations have included interests in subsidiaries and affiliated cannabis businesses operating in Europe, including Switzerland-based activities connected to hemp and cannabis commercialization. Publicly available disclosures have also referenced strategic relationships and acquisitions intended to expand distribution capabilities and product access within European markets. While the company has discussed international commercial ambitions, available public information suggests that its operational footprint and financial scale remain relatively limited compared with larger multinational cannabis operators. Data regarding certain partnerships, production assets, and long-term commercial agreements is inconclusive based on available public sources.

Strategic Position & Investments

CBD of Denver’s strategic direction has focused on positioning itself within the regulated European cannabis and CBD supply chain, particularly in jurisdictions with more developed hemp and low-THC cannabis frameworks. The company has publicly identified growth opportunities tied to wholesale cannabis distribution, cross-border product trading, and expanding consumer demand for CBD wellness products. Its strategy has emphasized operational exposure to the Swiss cannabis market, which has historically provided a more permissive regulatory environment relative to many other European jurisdictions.

The company has also pursued acquisitions and investments intended to strengthen its market access and distribution network. Public filings have referenced investments in cannabis-related entities and efforts to expand product offerings and trading relationships. CBD of Denver has periodically discussed broader participation in emerging cannabis industry segments, though publicly verifiable information regarding material technology ownership, proprietary intellectual property, or large-scale production infrastructure remains limited. Available disclosures indicate an emphasis on commercial distribution and market participation rather than vertically integrated cultivation or pharmaceutical research operations.

Geographic Footprint

CBD of Denver is incorporated in the United States but has historically concentrated much of its operational activity in Europe, particularly Switzerland. The company has identified the Swiss cannabis and CBD market as a central operational hub due to local regulatory conditions favorable to low-THC cannabis products. Public disclosures also indicate broader commercial interests across parts of the European Union, especially in wholesale and trading activities connected to hemp-derived products and cannabis flower distribution.

The company’s international orientation distinguishes it from many smaller U.S.-listed cannabis firms that focus primarily on domestic state-level operations. While its securities trade in the United States through the OTC market, operational emphasis has largely remained international. Available public information suggests that the company’s direct physical presence outside Europe is limited, and details regarding substantial operational infrastructure in additional regions are inconclusive based on available public sources.

Leadership & Governance

CBD of Denver’s leadership has historically emphasized participation in the evolving European cannabis economy through acquisitions, distribution relationships, and regulated market positioning. Public company disclosures indicate a management focus on expanding commercial relationships within the cannabis supply chain while adapting to changing regulatory conditions in Europe. As with many smaller OTC-listed companies, leadership composition and executive roles have changed periodically over time.

Key executives and officers publicly associated with the company in filings and disclosures include:

• Marcel Gamma – Chief Executive Officer
• Christian Hamberger – President
• Frank Kampfer – Executive leadership and operational roles referenced in public disclosures

Some executive appointments and governance details have varied across reporting periods. Investors and readers should consult the company’s most recent SEC filings and OTC market disclosures for the latest verified management information.